Biblio Discovery — Demo Discovery Service

23 hasil untuk "Jonathan Kitonsa"

Menampilkan 1–20 · 0,45 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.

    Julius Kiwanuka; Jacinta Mukulu Waila; Methuselah Muhindo Kahungu dkk.

    PLoS ONE, Vol. 15 No. 4 · 2020 · Inggris · DOAJ Scopus

    BACKGROUND:Retaining patients starting antiretroviral therapy (ART) and ensuring good adherence remain cornerstone of long-term viral suppression. In this era of test and treat (T&T) policy, ensuring that patients starting ART remain connected to HIV clinics is key to achieve the UNAIDS 90-90-90…

    Juga tersedia di: PLOS

  2. Artikel Jurnal Teks lengkap

    The immediate treatment outcomes and cost estimate for managing clinical measles in children admitted at Mulago Hospital: A retrospective cohort study

    Barbara Namugga; Ombeva Malande; Jonathan Kitonsa dkk.

    PLOS Global Public Health, Vol. 3 No. 7 · 2023 · Inggris · PLOS Scopus

    Over the recent years, the Ministry of Health in Uganda has reported multiple measles outbreaks in various districts despite the availability of a safe cost effective vaccine. Measles, especially among the unvaccinated can lead to serious complications including death while its management heavily…

  3. Artikel Jurnal Teks lengkap

    "Resilience amidst challenges": Healthcare users' experiences of access and utilisation of primary healthcare services during the COVID-19 pandemic in southwestern Uganda.

    Rachel Kawuma; Joseph Katongole; Abdmagidu Menya dkk.

    PLOS Global Public Health, Vol. 5 No. 8 · 2025 · Inggris · DOAJ Scopus

    Primary healthcare (PHC) systems are the first point of contact for healthcare users and are critical for disease prevention and early treatment. The COVID-19 pandemic overwhelmed PHC systems globally, including in sub-Saharan Africa, significantly impacting access to essential services. We…

    Juga tersedia di: PLOS

  4. Artikel Jurnal

    Changes in self-reported risky sexual behaviour indicators among adults receiving regular risk reduction counselling and optional initiation of pre-exposure prophylaxis in an HIV vaccine preparedness study in Masaka, Uganda

    Jonathan Kitonsa; Sheila Kansiime; Sylvia Kusemererwa dkk.

    Global Health Action, Vol. 16 No. 1 · 2023 · Inggris · DOAJ Scopus

    Background HIV risk reduction counselling may reduce risk-taking behaviours. Yet, concerns remain about risk compensation among individuals initiating pre-exposure prophylaxis (PrEP). Objective We assessed changes in risky sexual behaviour indicators among HIV vaccine preparedness study…

  5. Artikel Jurnal Teks lengkap

    Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda.

    Jonathan Kitonsa; Yunia Mayanja; Emmanuel Aling dkk.

    PLoS ONE, Vol. 14 No. 1 · 2019 · Inggris · DOAJ Scopus

    BackgroundCryptococcal meningitis (CCM) remains a leading cause of mortality amongst HIV infected patients in sub-Saharan Africa. When patients receive recommended therapy, mortality at 10 weeks has been reported to vary between 20 to 36%. However, mortality rate and factors affecting mortality…

    Juga tersedia di: PLOS

  6. Artikel Jurnal Teks lengkap

    Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis.

    Jonathan Kitonsa; Julius Kiwanuka; Zacchaeus Anywaine dkk.

    PLoS Neglected Tropical Diseases, Vol. 15 No. 3 · 2021 · Inggris · DOAJ Scopus

    BackgroundCryptococcal meningitis (CCM) remains one of the leading causes of mortality among HIV infected patients. Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients post-treatment is likely to be poor. Few studies have reported on QOL of CCM patients post…

    Juga tersedia di: PLOS

  7. Artikel Jurnal Teks lengkap

    Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda.

    Jonathan Kitonsa; Rebecca Nsubuga; Yunia Mayanja dkk.

    PLoS Neglected Tropical Diseases, Vol. 14 No. 11 · 2020 · Inggris · DOAJ Scopus

    Globally, early initiation of antiretroviral therapy for HIV led to a reduction in the estimated mortality from cryptococcal meningitis (CCM) from 624,700 in 2009 to 181,100 in 2014. However, CCM remains one of the leading causes of mortality among HIV infected patients especially in sub-Saharan…

    Juga tersedia di: PLOS

  8. Artikel Jurnal

    Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

    Jonathan Kitonsa; Abu-Baker Ggayi; Zacchaeus Anywaine dkk.

    Global Health Action, Vol. 13 No. 1 · 2020 · Inggris · DOAJ Scopus

    Background The 2013–2016 Ebola epidemic in West Africa is the worst ever caused by Ebolaviruses with over 28,000 human cases and 11,325 deaths. The World Health Organisation (WHO) declared the epidemic a public health crisis that required accelerated development of novel interventions including…

  9. Artikel Jurnal Teks lengkap

    Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda.

    Jonathan Kitonsa; Onesmus Kamacooko; Ubaldo Mushabe Bahemuka dkk.

    PLoS ONE, Vol. 16 No. 5 · 2021 · Inggris · DOAJ Scopus

    BackgroundHealthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in…

    Juga tersedia di: PLOS

  10. Artikel Jurnal

    A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences

    Jonathan Kitonsa; Onesmus Kamacooko; Eugene Ruzagira dkk.

    Human Vaccines & Immunotherapeutics, Vol. 19 No. 2 · 2023 · Inggris · DOAJ Scopus

    We report the screening and enrollment process for a phase I vaccine trial in Masaka, Uganda that investigated the safety and immunogenicity of a self-amplifying SARS-CoV-2 RNA vaccine amongst individuals with and without antibodies to SARS-CoV-2. Participant screening and enrollment were conducted…

  11. Artikel Jurnal

    Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved]

    Fafa Addo Boateng; Daniel Grint; Eugene Ruzagira dkk.

    Wellcome Open Research, Vol. 10 · 2025 · Inggris · DOAJ Scopus

    Long-acting (LA) injectable therapy as treatment for HIV-1 infection offers reduced dosing frequency, increased discretion and provides an alternative to two or three-drug daily oral combinations. A parenteral LA formulation of cabotegravir (CAB) and rilpivirine (RPV) given by intramuscular (IM)…

  12. Artikel Jurnal

    Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study

    Bolarinde J. Lawal; Katherine E. Gallagher; Jonathan Kitonsa dkk.

    International Journal of Infectious Diseases, Vol. 131 · 2023 · Inggris · DOAJ Scopus

    Objectives: We assessed the prevalence of immunoglobulin G (IgG) and IgM against four endemic human coronaviruses and two SARS-CoV-2 antigens among vaccinated and unvaccinated staff at health care centers in Uganda, Sierra Leone, and the Democratic Republic of Congo. Methods: The government health…

  13. Artikel Jurnal Teks lengkap

    Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

    Jonathan Kitonsa; Jennifer Serwanga; Hannah M. Cheeseman dkk.

    Vaccines, Vol. 13 No. 6 · 2025 · Inggris · DOAJ Scopus

    Background: The COVID-19 pandemic highlighted the need for innovative vaccine platforms that elicit durable immunity. Self-amplifying RNA (saRNA) vaccines offer rapid production and dose-sparing advantages over traditional mRNA platforms. In Uganda’s first SARS-CoV-2 vaccine trial (NCT04934111), we…

  14. Artikel Jurnal

    Practical application of good participatory practices for trials of emerging pathogens: Developing materials for use in ACTIV-3, -3b, and ACTIV-associated COVID-19 trials

    Paola del Carmen Guerra-de-Blas; Rubria Marines-Price; Olga Milman dkk.

    Journal of Clinical and Translational Science, Vol. 8 · 2024 · Inggris · DOAJ Scopus

    The emergence of the COVID-19 pandemic required an immediate global clinical research response. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines)-3 trials and the ACTIV-associated Outpatient Treatment with Anti-Coronavirus Immunoglobulin trial used Good Participatory…